HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simmonds, H A Articles by Singh, B Search for Related Content PubMed PubMed Citation Articles by Simmonds, H A Articles by Singh, B

Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency.

Developmental retardation was a prominent clinical feature in six infants from three kindreds deficient in the enzyme purine nucleoside phosphorylase (PNP) and was present before development of T cell immunodeficiency. Guanosine triphosphate (GTP) depletion was noted in the erythrocytes of all surviving homozygotes and was of equivalent magnitude to that found in the Lesch-Nyhan syndrome (complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency). The similarity between the neurological complications in both disorders indicates that the two major clinical consequences of complete PNP deficiency have differing aetiologies: neurological effects resulting from deficiency of the PNP enzyme products, which are the substrates for HGPRT, leading to functional deficiency of this enzyme. immunodeficiency caused by accumulation of the PNP enzyme substrates, one of which, deoxyguanosine, is toxic to T cells. These studies show the need to consider PNP deficiency (suggested by the finding of hypouricaemia) in patients with neurological dysfunction, as well as in T cell immunodeficiency. They suggest an important role for GTP in normal central nervous system function.

This article has been cited by other articles:

				V. Gandhi, J. M. Kilpatrick, W. Plunkett, M. Ayres, L. Harman, M. Du, S. Bantia, J. Davisson, W. G. Wierda, S. Faderl, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine) Blood, December 15, 2005; 106(13): 4253 - 4260. [Abstract] [Full Text] [PDF]

				M. S. Lim and K. S.J. Elenitoba-Johnson The Molecular Pathology of Primary Immunodeficiencies J. Mol. Diagn., May 1, 2004; 6(2): 59 - 83. [Full Text] [PDF]

				B. Tabarki, M. Yacoub, K. Tlili, A. Trabelsi, M. Dogui, and A. S. Essoussi Familial Spastic Paraplegia as the Presenting Manifestation in Patients With Purine Nucleoside Phosphorylase Deficiency J Child Neurol, February 1, 2003; 18(2): 140 - 141. [Abstract] [PDF]

				E. Arpaia, P. Benveniste, A. Di Cristofano, Y. Gu, I. Dalal, S. Kelly, M. Hershfield, P. P. Pandolfi, C. M. Roifman, and A. Cohen Mitochondrial Basis for Immune Deficiency: Evidence from Purine Nucleoside Phosphorylase-deficient Mice J. Exp. Med., June 19, 2000; 191(12): 2197 - 2208. [Abstract] [Full Text] [PDF]

				F. F. Snyder, J. P. Jenuth, E. R. Mably, and R. K. Mangat Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse PNAS, March 18, 1997; 94(6): 2522 - 2527. [Abstract] [Full Text] [PDF]